ClinicalTrials.gg
CompletedNCT03603106Updated May 14, 2021Results posted

Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions

A Phase 1/2 interventional study of P03277 and Placebo in Healthy Volunteers and Brain Lesion, sponsored by Guerbet. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-14.

Sponsored by Guerbet · Phase 1/2, Interventional, and Diagnostic

From the registry’s dates

  • Registered 4 years 7 months after the study started (first participant enrolled Nov 2013, registered Jul 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study was to evaluate the safety (clinical and biological) and pharmacokinetics (plasma and urine) profile of P03277 following single administration at ascending dose levels in healthy subjects.

Read the detailed description

This single-center, single ascending dose, phase I/IIa study was divided into 2 parts, involving both healthy subjects and patients with brain lesions:

  • Study Part I included healthy subjects: double-blind, randomized, placebo control;
  • Study Part II included patients with brain lesions: open-label.

In Part I, the following 6 dosing groups were investigated:

  • Group 1: 0.025 mmol/kg
  • Group 2: 0.05 mmol/kg
  • Group 3: 0.075 mmol/kg
  • Group 4: 0.1 mmol/kg
  • Group 5: 0.2 mmol/kg
  • Group 6: 0.3 mmol/kg

Healthy subjects were included and were then administered with P03277 or placebo and were to undergo MRI examination according to the randomization scheme.

In Part II, the following 4 doses groups were investigated:

  • Group 7: 0.05 mmol/kg
  • Group 8: 0.075 mmol/kg
  • Group 9: 0.1 mmol/kg
  • Group 10: 0.2 mmol/kg

Patients with brain lesions were included and were then administered with P03277 and underwent MRI examination.

02

Conditions studied

  • Healthy Volunteers
  • Brain Lesion
03

In context

Lead sponsor

Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Part I: Subjects between 18 and 45 years old (inclusive), with a (BMI) of 18 to 30 kg/m² (exclusive) and in a good health.
  • Part II: Patients 18 years old and older and having at least one brain lesion with a disruption of the blood brain barrier (BBB) and/or with abnormal vascularity in the brain. This/these lesion(s) must have been detected by previous imaging evaluation (Computed Tomography or MRI).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Part I (Phase I)

    In each dose group (0.025, 0.05, 0.075, 0.1, 0.2 and 0.3 mmol/kg), 9 healthy subjects were to be included: 6 subjects received P03277 and 3 subjects received placebo in one single intravenous administration.

    Drug: P03277 · Drug: Placebo

  • Experimental
    Part II (Phase IIA)

    In each dose group (0.05, 0.075, 0.1 and 0.2 mmol/kg), all 3 patients received one single intravenous administration of P03277.

    Drug: P03277

Interventions

  • DrugP03277

    Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s. Part II: P03277 was administered intravenously with a flow rate of 2 mL/s.

    Also known as: Gadopiclenol

  • DrugPlacebo

    Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s. Part II: Placebo was administered intravenously with a flow rate of 2 mL/s.

    Also known as: NaCl 0.9%

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter Cmax

    Cmax = maximum concentration measured. Blood samples were taken to assess the P03277 concentration.

    Time frame: From baseline (30 minutes before injection) to 24 hours post-injection

  2. PK Parameter T1/2

    T1/2 = terminal elimination half-life of the compound. Blood samples were taken to assess the P03277 concentration.

    Time frame: From baseline (30 minutes before injection) to 24 hours post-injection

  3. PK Parameter Cl

    Cl = total clearance. Blood samples were taken to assess the P03277 concentration.

    Time frame: From baseline (30 minutes before injection) to 24 hours post-injection

  4. PK Parameter Vd

    Vd = volume of distribution. Blood samples were taken to assess the P03277 concentration.

    Time frame: From baseline (30 minutes before injection) to 24 hours post-injection

07

Results

Posted Jul 12, 2019

Participant flow

Participant flow — Overall Study
MilestonePart I (Phase I) P03277 0.025 mmol/kgPart I (Phase I) P03277 0.05 mmol/kgPart I (Phase I) P03277 0.075 mmol/kgPart I (Phase I) P03277 0.1 mmol/kgPart I (Phase I) P03277 0.2 mmol/kgPart I (Phase I) P03277 0.3 mmol/kgPart I (Phase I) PlaceboPart II (Phase IIA) P03277 0.05 mmol/kgPart II (Phase IIA) P03277 0.075 mmol/kgPart II (Phase IIA) P03277 0.1 mmol/kgPart II (Phase IIA) P03277 0.2 mmol/kg
Started666666183333
Completed666666183333
Not completed00000000000

Outcome measures

PrimaryPharmacokinetic (PK) Parameter Cmax

Cmax = maximum concentration measured. Blood samples were taken to assess the P03277 concentration.

Time frame:
From baseline (30 minutes before injection) to 24 hours post-injection
Reported as:
Mean · µg/mL
Pharmacokinetic (PK) Parameter Cmax
µg/mLPart I (Phase I) P03277 0.025 mmol/kgPart I (Phase I) P03277 0.05 mmol/kgPart I (Phase I) P03277 0.075 mmol/kgPart I (Phase I) P03277 0.1 mmol/kgPart I (Phase I) P03277 0.2 mmol/kgPart I (Phase I) P03277 0.3 mmol/kgPart II (Phase IIA) 0.05 mmol/kgPart II (Phase IIA) 0.075 mmol/kgPart II (Phase IIA) 0.1 mmol/kgPart II (Phase IIA) 0.2 mmol/kg
Pharmacokinetic (PK) Parameter Cmax248.7 ± 54.5524.5 ± 69.9698.7 ± 378.9992.0 ± 233.12097.6 ± 572.33916.4 ± 1114.8370.8 ± 117.6618.2 ± 439.7701.6 ± 48.51434.9 ± 651.5
PrimaryPK Parameter T1/2

T1/2 = terminal elimination half-life of the compound. Blood samples were taken to assess the P03277 concentration.

Time frame:
From baseline (30 minutes before injection) to 24 hours post-injection
Reported as:
Mean · hours
PK Parameter T1/2
hoursPart I (Phase I) P03277 0.025 mmol/kgPart I (Phase I) P03277 0.05 mmol/kgPart I (Phase I) P03277 0.075 mmol/kgPart I (Phase I) P03277 0.1 mmol/kgPart I (Phase I) P03277 0.2 mmol/kgPart I (Phase I) P03277 0.3 mmol/kgPart II (Phase IIA) 0.05 mmol/kgPart II (Phase IIA) 0.075 mmol/kgPart II (Phase IIA) 0.1 mmol/kgPart II (Phase IIA) 0.2 mmol/kg
PK Parameter T1/21.65 ± 0.431.50 ± 0.221.58 ± 0.301.73 ± 0.261.82 ± 0.352.09 ± 0.151.90 ± 0.042.04 ± 0.061.79 ± 0.171.94 ± 0.06
PrimaryPK Parameter Cl

Cl = total clearance. Blood samples were taken to assess the P03277 concentration.

Time frame:
From baseline (30 minutes before injection) to 24 hours post-injection
Reported as:
Mean · mL/min
PK Parameter Cl
mL/minPart I (Phase I) P03277 0.025 mmol/kgPart I (Phase I) P03277 0.05 mmol/kgPart I (Phase I) P03277 0.075 mmol/kgPart I (Phase I) P03277 0.1 mmol/kgPart I (Phase I) P03277 0.2 mmol/kgPart I (Phase I) P03277 0.3 mmol/kgPart II (Phase IIA) 0.05 mmol/kgPart II (Phase IIA) 0.075 mmol/kgPart II (Phase IIA) 0.1 mmol/kgPart II (Phase IIA) 0.2 mmol/kg
PK Parameter Cl91.7 ± 8.5100.1 ± 9.5106.4 ± 20.796.1 ± 11.8101.3 ± 10.9102.2 ± 19.0105.3 ± 13.5106.5 ± 15.7108.6 ± 5109.9 ± 18.2
PrimaryPK Parameter Vd

Vd = volume of distribution. Blood samples were taken to assess the P03277 concentration.

Time frame:
From baseline (30 minutes before injection) to 24 hours post-injection
Reported as:
Mean · mL
PK Parameter Vd
mLPart I (Phase I) P03277 0.025 mmol/kgPart I (Phase I) P03277 0.05 mmol/kgPart I (Phase I) P03277 0.075 mmol/kgPart I (Phase I) P03277 0.1 mmol/kgPart I (Phase I) P03277 0.2 mmol/kgPart I (Phase I) P03277 0.3 mmol/kgPart II (Phase IIA) 0.05 mmol/kgPart II (Phase IIA) 0.075 mmol/kgPart II (Phase IIA) 0.1 mmol/kgPart II (Phase IIA) 0.2 mmol/kg
PK Parameter Vd13203 ± 412212945 ± 169214312 ± 274214351 ± 264515922 ± 322418487 ± 357517320 ± 194218796 ± 247816823 ± 80418355 ± 2522

Adverse events

Collected over For Part I: adverse events were collected from subjects' enrollment until 7 days after the product (P03277 or placebo) administration. For Part II: adverse events were collected from patients' enrollment until 1 day after P03277 administration.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part I (Phase I) P03277 0.025 mmol/kg0/6 (0%)0/6 (0%)2/6 (33.3%)
Part I (Phase I) P03277 0.05 mmol/kg0/6 (0%)0/6 (0%)3/6 (50%)
Part I (Phase I) P03277 0.075 mmol/kg0/6 (0%)0/6 (0%)2/6 (33.3%)
Part I (Phase I) P03277 0.1 mmol/kg0/6 (0%)0/6 (0%)4/6 (66.7%)
Part I (Phase I) P03277 0.2 mmol/kg0/6 (0%)0/6 (0%)5/6 (83.3%)
Part I (Phase I) P03277 0.3 mmol/kg0/6 (0%)0/6 (0%)3/6 (50%)
Part I (Phase I) Placebo0/18 (0%)0/18 (0%)11/18 (61.1%)
Part II (Phase IIA) P03277 0.05 mmol/kg0/3 (0%)0/3 (0%)1/3 (33.3%)
Part II (Phase IIA) P03277 0.075 mmol/kg0/3 (0%)1/3 (33.3%)1/3 (33.3%)
Part II (Phase IIA) P03277 0.1 mmol/kg0/3 (0%)0/3 (0%)1/3 (33.3%)
Part II (Phase IIA) P03277 0.2 mmol/kg0/3 (0%)0/3 (0%)2/3 (66.7%)
Most frequent serious events
Most frequent serious events
EventPart I (Phase I) P03277 0.025 mmol/kgPart I (Phase I) P03277 0.05 mmol/kgPart I (Phase I) P03277 0.075 mmol/kgPart I (Phase I) P03277 0.1 mmol/kgPart I (Phase I) P03277 0.2 mmol/kgPart I (Phase I) P03277 0.3 mmol/kgPart I (Phase I) PlaceboPart II (Phase IIA) P03277 0.05 mmol/kgPart II (Phase IIA) P03277 0.075 mmol/kgPart II (Phase IIA) P03277 0.1 mmol/kgPart II (Phase IIA) P03277 0.2 mmol/kg
Abortion inducedSurgical and medical procedures0/60/60/60/60/60/60/180/31/30/30/3
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPart I (Phase I) P03277 0.025 mmol/kgPart I (Phase I) P03277 0.05 mmol/kgPart I (Phase I) P03277 0.075 mmol/kgPart I (Phase I) P03277 0.1 mmol/kgPart I (Phase I) P03277 0.2 mmol/kgPart I (Phase I) P03277 0.3 mmol/kgPart I (Phase I) PlaceboPart II (Phase IIA) P03277 0.05 mmol/kgPart II (Phase IIA) P03277 0.075 mmol/kgPart II (Phase IIA) P03277 0.1 mmol/kgPart II (Phase IIA) P03277 0.2 mmol/kg
Catheter site painGeneral disorders0/61/60/60/63/60/61/180/30/30/31/3
Injection site painGeneral disorders1/60/60/60/62/61/63/180/30/30/30/3
HeadacheNervous system disorders0/61/60/61/61/62/65/180/30/30/31/3
Influenza like illnessGeneral disorders0/60/61/60/60/60/60/180/30/31/30/3
Decreased appetiteMetabolism and nutrition disorders0/60/60/60/60/60/60/181/30/30/30/3
PregnancyPregnancy, puerperium and perinatal conditions0/60/60/60/60/60/60/180/31/30/30/3
Injection site oedemaGeneral disorders0/60/60/61/61/60/61/180/30/30/30/3
FatigueGeneral disorders0/60/60/61/60/60/61/180/30/30/30/3
Catheter site dermatitisGeneral disorders0/61/60/60/60/60/60/180/30/30/30/3
Injection site coldnessGeneral disorders0/60/60/60/61/60/60/180/30/30/30/3

Baseline characteristics

All patients who received one injection of product (placebo or P03277 for Part I, P03277 for Part II).

Age, Continuous
Age, Continuous(years)Part I (Phase I) P03277 0.025 mmol/kgPart I (Phase I) P03277 0.05 mmol/kgPart I (Phase I) P03277 0.075 mmol/kgPart I (Phase I) P03277 0.1 mmol/kgPart I (Phase I) P03277 0.2 mmol/kgPart I (Phase I) P03277 0.3 mmol/kgPart I (Phase I) PlaceboPart II (Phase IIA) P03277 0.05 mmol/kgPart II (Phase IIA) P03277 0.075 mmol/kgPart II (Phase IIA) P03277 0.1 mmol/kgPart II (Phase IIA) P03277 0.2 mmol/kgTotal
Median26.0 (22 to 30)25.5 (21 to 37)27.5 (23 to 40)25.5 (23 to 41)23.0 (18 to 36)33.5 (23 to 42)26.5 (19 to 43)40.0 (37 to 50)56.0 (25 to 57)56.0 (53 to 61)53.0 (50 to 58)28.0 (18 to 61)
Sex: Female, Male
Sex: Female, Male(Participants)Part I (Phase I) P03277 0.025 mmol/kgPart I (Phase I) P03277 0.05 mmol/kgPart I (Phase I) P03277 0.075 mmol/kgPart I (Phase I) P03277 0.1 mmol/kgPart I (Phase I) P03277 0.2 mmol/kgPart I (Phase I) P03277 0.3 mmol/kgPart I (Phase I) PlaceboPart II (Phase IIA) P03277 0.05 mmol/kgPart II (Phase IIA) P03277 0.075 mmol/kgPart II (Phase IIA) P03277 0.1 mmol/kgPart II (Phase IIA) P03277 0.2 mmol/kgTotal
Female3433338121132
Male32333310212234
Weight
Weight(kg)Part I (Phase I) P03277 0.025 mmol/kgPart I (Phase I) P03277 0.05 mmol/kgPart I (Phase I) P03277 0.075 mmol/kgPart I (Phase I) P03277 0.1 mmol/kgPart I (Phase I) P03277 0.2 mmol/kgPart I (Phase I) P03277 0.3 mmol/kgPart I (Phase I) PlaceboPart II (Phase IIA) P03277 0.05 mmol/kgPart II (Phase IIA) P03277 0.075 mmol/kgPart II (Phase IIA) P03277 0.1 mmol/kgPart II (Phase IIA) P03277 0.2 mmol/kgTotal
Median81.65 (52.2 to 87.4)71.60 (54.0 to 83.6)65.00 (56.4 to 93.0)72.50 (62.0 to 99.2)69.30 (68.2 to 87.6)72.50 (61.6 to 88.6)67.90 (56.8 to 89.4)87.20 (85.8 to 89.0)80.40 (71.2 to 87.4)87.20 (82.4 to 102.8)85.80 (79.4 to 101.6)72.85 (52.2 to 102.8)
08

Study locations

1 site
  • Clinical Pharmacology unit, SGS Life Science Services
    Antwerpen, 2060, Belgium
09

References and documents

Publications

  • Hao J, Bourrinet P, Desche P. Assessment of Pharmacokinetic, Pharmacodynamic Profile, and Tolerance of Gadopiclenol, A New High Relaxivity GBCA, in Healthy Subjects and Patients With Brain Lesions (Phase I/IIa Study). Invest Radiol. 2019 Jul;54(7):396-402. doi: 10.1097/RLI.0000000000000556. PubMed 30870257 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2013 to primary completion in Apr 2015, 16 months.

Results were first posted in Jul 2019, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2018
First posted
Jul 27, 2018
StartActual
Nov 25, 2013
Primary completionActual
Apr 17, 2015
CompletionActual
Apr 17, 2015
Results first posted
Jul 12, 2019
Last update
May 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03603106
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Jul 27, 2018
Start date
Nov 25, 2013
Primary completion
Apr 17, 2015
Completion
Apr 17, 2015
Results posted
Jul 12, 2019
Last update
May 14, 2021

Study contacts

Wouter Haazen, MD
principal investigator · SGS Clinical Pharmacology Unit

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadopiclenol

Start the discussion